帕博利珠单抗联合仑伐替尼治疗复发性子宫内膜癌的真实世界经验:韩国多中心研究
该韩国三中心回顾性队列纳入48例复发性子宫内膜癌患者,接受帕博利珠单抗联合仑伐替尼治疗,最佳客观缓解率23.8%(95%CI 11.9-38.1),疾病控制率76.2%(95%CI 61.9-88.1);血清CA-125是唯一无进展生存预后因素(校正HR 4.41,95%CI 1.19-16.36,p=0.03)。
要点
- 48例复发性子宫内膜癌患者接受帕博利珠单抗联合仑伐替尼,最佳客观缓解率23.8%,疾病控制率76.2%。
- 56.2%患者经历至少一次仑伐替尼减量,16.7%因治疗相关不良事件停用仑伐替尼。
- 血清CA-125是唯一无进展生存预后因素(校正HR 4.41,95%CI 1.19-16.36,p=0.03)。
核心结论
- 在韩国复发性子宫内膜癌患者中,帕博利珠单抗联合仑伐替尼的真实世界治疗缓解率低于临床试验,治疗中断率与临床试验相似。
研究设计与样本
- 多中心回顾性队列研究,纳入2020年3月至2021年5月在韩国三家三级医院接受帕博利珠单抗联合仑伐替尼治疗的复发性子宫内膜癌患者,共48例。
主要发现
- 患者中位年龄62.5岁(范围42-78岁),最常见组织学亚型为子宫内膜样腺癌(43.8%),其次为浆液性腺癌(25.0%)。
- 91.7%患者为错配修复功能完整肿瘤,中位治疗4.5个周期,最佳客观缓解率23.8%(95%CI 11.9-38.1),疾病控制率76.2%(95%CI 61.9-88.1)。
- 56.2%患者经历至少一次仑伐替尼减量,16.7%经历仑伐替尼中断,16.7%患者因治疗相关不良事件停用仑伐替尼。
- 最常见治疗相关不良事件为疲乏(18.8%)、高血压(16.7%)和甲状腺功能减退(14.6%)。
- 血清CA-125是唯一无进展生存预后因素(校正HR 4.41,95%CI 1.19-16.36,p=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effectiveness and safety of pembrolizumab and lenvatinib (PEMBRO+LEN) for recurrent endometrial cancer (EC) in a real-world setting. METHODS: This multicenter retrospective cohort study included patients with recurrent EC who received PEMBRO+LEN between March 2020 and May 2021 at three tertiary hospitals in Korea. We summarized patient characteristics and evaluated the response rates, survival outcomes, and treatment-related adverse events (AEs). RESULTS: In total, 48 patients were included in the study. The median age of the patients was 62.5 (range, 42-78) years. The most common histologic subtype was endometrioid adenocarcinoma (43.8%), followed by serous adenocarcinoma (25.0%). Most patients (91.7%) had mismatch repair-proficient tumors. Patients received PEMBRO+LEN for a median of 4.5 cycles, during which the best objective response rate and disease control rate were 23.8% (95% CI, 11.9-38.1) and 76.2% (95% CI, 61.9-88.1), respectively. Overall, 56.2% of patients experienced LEN dose reduction once or more and 16.7% experienced LEN interruption. The most common treatment-related AEs were fatigue (18.8%), hypertension (16.7%), and hypothyroidism (14.6%). Total of 8 patients (16.7%) discontinued LEN during the treatment because of treatment-related AEs. Serum CA-125 level was the only prognostic factor for progression-free survival (adjusted hazard ratio, 4.41; 95% confidence interval, 1.19-16.36; p = 0.03). CONCLUSIONS: In our real-world study, Korean patients with recurrent EC who received PEMBRO+LEN showed lower treatment response rate and similar treatment discontinuation rate, compared to clinical trials.
引用
- Kim J, Noh JJ, Lee TK, et al. Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea. Gynecol Oncol. 2022. PMID: 35277278. doi:10.1016/j.ygyno.2022.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。